# Clinical Development of COVID-19 Therapeutics

> **NIH NIH N01** · ALIGOS THERAPEUTICS, INC. · 2024 · $1,300,776

## Abstract

To support the advanced development of candidate therapeutics for a virus covered under the Antiviral Program for Pandemics. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase I clinical trial in renal and hepatic impaired patients.

## Key facts

- **NIH application ID:** 11063909
- **Project number:** 75N93023C00052-P00001-9999-1
- **Recipient organization:** ALIGOS THERAPEUTICS, INC.
- **Principal Investigator:** STANLEY WANG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,300,776
- **Award type:** —
- **Project period:** 2023-09-22 → 2026-02-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11063909

## Citation

> US National Institutes of Health, RePORTER application 11063909, Clinical Development of COVID-19 Therapeutics (75N93023C00052-P00001-9999-1). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/11063909. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*